BioStock Studio: Expres2ion’s CEO gives status update
Biotech ExpreS2ion Biotechnologies – that develops vaccines for covid-19, breast cancer, influenza and malaria – is currently conducting a rights issue of 73 million SEK. CEO Bent U. Frandsen visited BioStock’s studio to give a status update on the covid-19 project, which is being developed together with Bavarian Nordic, and to tell us more about the rights issue.
Watch the interview with ExpreS2ion Biotechnologies CEO Bent U. Frandsen below.